Leerink Partnrs Comments on Tourmaline Bio FY2025 Earnings

Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Leerink Partnrs lowered their FY2025 earnings per share estimates for shares of Tourmaline Bio in a research report issued on Monday, May 5th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings per share of ($3.71) for the year, down from their previous estimate of ($3.22). The consensus estimate for Tourmaline Bio's current full-year earnings is ($3.02) per share. Leerink Partnrs also issued estimates for Tourmaline Bio's FY2026 earnings at ($4.28) EPS, FY2027 earnings at ($5.89) EPS, FY2028 earnings at ($6.73) EPS and FY2029 earnings at ($3.45) EPS.

TRML has been the subject of a number of other research reports. Lifesci Capital assumed coverage on Tourmaline Bio in a research note on Monday, February 24th. They issued an "outperform" rating and a $58.00 price objective for the company. HC Wainwright reiterated a "buy" rating and issued a $50.00 target price on shares of Tourmaline Bio in a research note on Monday. Wedbush increased their target price on shares of Tourmaline Bio from $42.00 to $43.00 and gave the company an "outperform" rating in a report on Friday, March 14th. Finally, Chardan Capital restated a "buy" rating and set a $70.00 price target on shares of Tourmaline Bio in a report on Monday. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $49.33.

Tourmaline Bio Trading Up 5.8 %

TRML opened at $15.39 on Thursday. The company has a market cap of $395.29 million, a P/E ratio of -5.46 and a beta of 2.11. The company has a fifty day moving average price of $15.36 and a two-hundred day moving average price of $18.95. Tourmaline Bio has a 1-year low of $11.56 and a 1-year high of $29.79.

Tourmaline Bio (NASDAQ:TRML - Get Free Report) last posted its quarterly earnings results on Friday, May 2nd. The company reported ($0.89) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.91) by $0.02.

Hedge Funds Weigh In On Tourmaline Bio

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Adage Capital Partners GP L.L.C. bought a new stake in Tourmaline Bio in the fourth quarter worth about $12,168,000. Pictet Asset Management Holding SA raised its holdings in shares of Tourmaline Bio by 69.9% in the 4th quarter. Pictet Asset Management Holding SA now owns 419,883 shares of the company's stock worth $8,515,000 after purchasing an additional 172,743 shares during the period. Federated Hermes Inc. lifted its stake in Tourmaline Bio by 13,036.0% in the first quarter. Federated Hermes Inc. now owns 121,245 shares of the company's stock valued at $1,844,000 after purchasing an additional 120,322 shares during the last quarter. Schonfeld Strategic Advisors LLC grew its holdings in Tourmaline Bio by 50.5% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 298,239 shares of the company's stock valued at $6,048,000 after purchasing an additional 100,139 shares during the period. Finally, Velan Capital Investment Management LP increased its position in Tourmaline Bio by 28.0% in the fourth quarter. Velan Capital Investment Management LP now owns 423,795 shares of the company's stock worth $8,595,000 after buying an additional 92,605 shares during the last quarter. 91.89% of the stock is owned by hedge funds and other institutional investors.

About Tourmaline Bio

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.